ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Minnesota » Hematology Oncology

Top Hematology Oncology Prescribers in Minnesota

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
HANI ALKHATIB MB, BCH

Hematology Oncology

2,575

$1.22M

254
216 are 65+

17%
patients receiving schedule two controlled substances

Avg: 14%

15%
patients receiving schedule three controlled substances

Avg: 5%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

15%
prescriptions for brand name drugs

Avg: 17%

$474
Average prescription price

Avg: $447

DAVID KING M.D.

Hematology Oncology

2,564

$483K

249
208 are 65+

22%
patients receiving schedule two controlled substances

Avg: 14%

16%
patients receiving schedule three controlled substances

Avg: 5%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 17%

$188
Average prescription price

Avg: $447

JOHN TATE MD

Hematology Oncology

2,550

$1.13M

170
152 are 65+

25%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 5%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 17%

$442
Average prescription price

Avg: $447

DOUGLAS RAUSCH MD

Hematology Oncology

1,843

$611K

156
80 are 65+

28%
patients receiving schedule two controlled substances

Avg: 14%

11%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 17%

$332
Average prescription price

Avg: $447

HAROLD LONDER M.D.

Hematology Oncology

1,560

$952K

267
234 are 65+

13%
patients receiving schedule two controlled substances

Avg: 14%

14%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 17%

$611
Average prescription price

Avg: $447

AVANTI MEHROTRA MD

Hematology Oncology

1,419

$582K

198
175 are 65+

11%
patients receiving schedule two controlled substances

Avg: 14%

7%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

12%
prescriptions for brand name drugs

Avg: 17%

$410
Average prescription price

Avg: $447

BIRENDRA KUMAR MD

Hematology Oncology

1,400

$786K

222
193 are 65+

9%
patients receiving schedule two controlled substances

Avg: 14%

9%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 17%

$562
Average prescription price

Avg: $447

NOEL LAUDI M.D.

Hematology Oncology

1,357

$326K

194
158 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

15%
patients receiving schedule three controlled substances

Avg: 5%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

14%
prescriptions for brand name drugs

Avg: 17%

$240
Average prescription price

Avg: $447

MARK HAUGE MD

Hematology Oncology

1,354

$723K

215
190 are 65+

15%
patients receiving schedule two controlled substances

Avg: 14%

8%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 17%

$534
Average prescription price

Avg: $447

VLADIMIR HUGEC M.D.

Hematology Oncology

1,327

$612K

196
167 are 65+

21%
patients receiving schedule two controlled substances

Avg: 14%

8%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 17%

$461
Average prescription price

Avg: $447

JADE ANDERSON M.D.

Hematology Oncology

1,272

$307K

182
154 are 65+

21%
patients receiving schedule two controlled substances

Avg: 14%

14%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

15%
prescriptions for brand name drugs

Avg: 17%

$241
Average prescription price

Avg: $447

ROBERT DELAUNE M.D.

Hematology Oncology

1,254

$707K

203
180 are 65+

18%
patients receiving schedule two controlled substances

Avg: 14%

13%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 17%

$564
Average prescription price

Avg: $447

STEPHEN MANN M.D.

Hematology Oncology

1,242

$450K

155
131 are 65+

21%
patients receiving schedule two controlled substances

Avg: 14%

10%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 17%

$362
Average prescription price

Avg: $447

UZMA ALI MBBS

Hematology Oncology

1,217

$228K

114
92 are 65+

12%
patients receiving schedule two controlled substances

Avg: 14%

11%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 17%

$187
Average prescription price

Avg: $447

MARK LITZOW M.D.

Hematology Oncology

1,149

$332K

58
33 are 65+

0%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 17%

$289
Average prescription price

Avg: $447

STUART BLOOM M.D.

Hematology Oncology

1,125

$581K

162
135 are 65+

22%
patients receiving schedule two controlled substances

Avg: 14%

9%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 17%

$517
Average prescription price

Avg: $447

BRET FRIDAY MD

Hematology Oncology

1,115

$723K

239
194 are 65+

18%
patients receiving schedule two controlled substances

Avg: 14%

9%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 17%

$649
Average prescription price

Avg: $447

DAHLIA ELKADI MB B CH

Hematology Oncology

1,115

$616K

151
141 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 17%

$552
Average prescription price

Avg: $447

RONALD HALVORSON MD

Hematology Oncology

1,102

$205K

172
158 are 65+

16%
patients receiving schedule two controlled substances

Avg: 14%

11%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

11%
prescriptions for brand name drugs

Avg: 17%

$186
Average prescription price

Avg: $447

ANDRZEJ PETRYK M.D.

Hematology Oncology

1,083

$427K

177
141 are 65+

12%
patients receiving schedule two controlled substances

Avg: 14%

7%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 17%

$395
Average prescription price

Avg: $447

MOHAMED HUSSEIN MD

Hematology Oncology

1,083

$551K

163
137 are 65+

20%
patients receiving schedule two controlled substances

Avg: 14%

9%
patients receiving schedule three controlled substances

Avg: 5%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

12%
prescriptions for brand name drugs

Avg: 17%

$509
Average prescription price

Avg: $447

PUNEET CHEEMA MD

Hematology Oncology

1,046

$544K

204
182 are 65+

8%
patients receiving schedule two controlled substances

Avg: 14%

5%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

14%
prescriptions for brand name drugs

Avg: 17%

$520
Average prescription price

Avg: $447

PAUL THURMES M.D.

Hematology Oncology

1,010

$636K

143
125 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

8%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

14%
prescriptions for brand name drugs

Avg: 17%

$630
Average prescription price

Avg: $447

MARK MENGE

Hematology Oncology

1,006

$774K

168
147 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

7%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 17%

$769
Average prescription price

Avg: $447

DANIEL ANDERSON MD

Hematology Oncology

989

$190K

138
111 are 65+

19%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 5%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

13%
prescriptions for brand name drugs

Avg: 17%

$192
Average prescription price

Avg: $447

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank